Wall Street analysts collectively estimate these companies are worth materially less than their current market prices. The table below ranks stocks by implied downside to consensus price targets. Data sourced from Capital IQ.
Rank | Ticker | Analyst Downside | EV/NTM EBITDA | Short Interest % | 1Y Revenue Growth | Insider Ownership % |
|---|---|---|---|---|---|---|
1 | FCEL | -52.4% | NM | 10.3% | 48.3% | 0.2% |
2 | REPL | -50.7% | NM | 28.7% | N/A | 1.8% |
3 | KORE | -45.6% | N/A | 0.7% | -0.9% | 11.0% |
4 | NVTS | -42.3% | NM | 15.6% | -45.4% | 11.4% |
5 | LESL | -41.7% | 22.6x | 18.8% | -8.8% | 2.5% |
6 | VSH | -40.6% | 16.6x | 8.3% | 9.9% | 3.0% |
7 | AGL | -37.7% | 87.5x | 3.8% | -2.8% | 1.8% |
8 | AEHR | -35.3% | NM | 15.2% | -26.4% | 6.2% |
9 | HOV | -32.1% | 14.2x | 6.1% | -4.7% | 19.2% |
10 | RFIL | -29.9% | 21.3x | 1.5% | 13.8% | 6.5% |
11 | LFVN | -29.8% | 8.8x | 28.5% | -12.2% | 16.2% |
12 | ACDC | -29.7% | 9.0x | 2.5% | -18.9% | 4.5% |
13 | PBYI | -28.9% | N/A | 8.2% | -2.4% | 15.1% |
14 | COOK | -28.2% | 9.0x | 1.9% | -15.3% | 13.4% |
15 | HYLN | -27.5% | NM | 7.3% | 191.2% | 22.6% |
16 | WOLF | -27.4% | N/A | 57.3% | -6.4% | 0.0% |
17 | CAR | -26.5% | 34.9x | 16.5% | 0.7% | 1.9% |
18 | ALX | -26.5% | N/A | 7.1% | -3.7% | 16.1% |
19 | IPI | -25.6% | 8.1x | 2.1% | 12.9% | 2.9% |
20 | MRAM | -23.9% | 28.3x | 12.1% | 15.9% | 6.1% |
21 | FTNT | -23.8% | 35.6x | 2.7% | 15.7% | 15.8% |
22 | AMCX | -23.5% | 5.6x | 14.7% | -3.4% | 2.4% |
23 | BAND | -22.8% | 21.0x | 2.9% | 4.9% | 6.8% |
24 | ALAB | -22.7% | 78.9x | 7.2% | 104.2% | 10.4% |
25 | ENPH | -22.2% | 22.2x | 22.8% | -1.6% | 3.0% |
26 | HTLD | -21.2% | 8.1x | 2.8% | -23.5% | 6.6% |
27 | VSTS | -21.0% | 9.3x | 6.2% | -0.8% | 15.9% |
28 | RXO | -20.8% | 36.0x | 8.7% | 13.1% | 0.7% |
29 | IRDM | -20.0% | 13.5x | 5.4% | 4.1% | 2.4% |
30 | CVLG | -19.6% | 8.2x | 3.0% | 7.2% | 39.9% |
The 10 Most Compelling Short Candidates
1. FCEL
FuelCell Energy remains one of the market's most persistent examples of a compelling narrative paired with weak economics. Despite decades of operations, the company continues to struggle to generate sustainable profitability and free cash flow. The stock trades materially above analyst targets while investors continue to underwrite a future hydrogen economy that has yet to produce attractive shareholder returns. Significant dilution, ongoing losses, and capital requirements create a difficult path to justify the current valuation.
2. NVTS
Navitas Semiconductor has an exciting technology story centered around gallium nitride power semiconductors, but the market continues to value the company as if future dominance is already assured. Revenue growth has deteriorated sharply while valuation remains disconnected from operating fundamentals. The combination of negative analyst upside, declining revenue, and continued losses creates a difficult risk-reward profile.
3. AEHR
Aehr Test Systems benefited enormously from enthusiasm surrounding electric vehicle silicon carbide testing. The problem is that expectations became substantially larger than the addressable opportunity. Revenue growth has slowed dramatically while investors continue to price the company for a much larger future market. Customer concentration and cyclical semiconductor demand add additional risk.
4. AGL
agilon health was once viewed as a disruptive healthcare platform with substantial operating leverage. Instead, profitability has remained elusive while growth has decelerated. The stock still trades above analyst targets despite weak economics and limited evidence of durable competitive advantages. Healthcare roll-up models often look attractive until reimbursement realities emerge.
5. WOLF
Wolfspeed possesses valuable technology but operates in one of the most capital-intensive segments of semiconductors. Massive manufacturing investments, ongoing losses, and execution challenges have created a difficult financial position. The market continues to price future success despite significant balance sheet and operational risks.
6. ALAB
Astera Labs is a high-quality company operating in an attractive AI infrastructure market. The concern is valuation rather than business quality. The stock trades at an extraordinary multiple while investors assume AI spending remains elevated indefinitely. Excellent businesses can still produce poor returns when purchased at excessive valuations.
7. ENPH
Enphase remains one of the strongest businesses in residential solar, but the industry faces significant headwinds. Higher interest rates, slowing residential installations, and policy uncertainty have pressured demand. Despite deteriorating industry fundamentals, the valuation still assumes a much stronger recovery than current trends support.
8. MRAM
Everspin Technologies operates in a niche memory segment with attractive intellectual property but limited scale. Investors continue to extrapolate future growth opportunities despite a relatively small addressable market and inconsistent financial performance. The valuation appears difficult to justify relative to long-term earnings power.
9. CAR
Avis Budget has benefited from extraordinary post-pandemic vehicle pricing and rental economics. Those tailwinds are unlikely to persist indefinitely. The company faces cyclical pressures, declining used vehicle values, and normalization of travel-related demand. The market appears to be capitalizing peak-cycle profitability.
10. REPL
Replimune represents a classic biotechnology risk profile. Investors are assigning significant value to future clinical success before commercial economics have been demonstrated. While clinical outcomes can create upside, the combination of analyst downside, high short interest, and binary development risks creates a highly speculative setup.
The Common Thread
The market's worst investments rarely look dangerous.
Most combine:
• Great stories
• Exciting future narratives
• Significant investor enthusiasm
• Limited current earnings power
The Oddsmaker is not attempting to predict which technologies succeed.
The objective is to identify situations where expectations appear dramatically disconnected from fundamentals.
$FCEL, $NVTS, $AEHR, $AGL, $WOLF, $ALAB, $ENPH, $MRAM, $CAR, and $REPL all share one characteristic:
The market currently expects far more than analysts, fundamentals, and business economics appear to justify.